✨ Free AI Report
Moleculin Biotech, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Moleculin Biotech, Inc.
Company Research

Moleculin Biotech, Inc.: Business Overview, Financials & Competitive Analysis

Moleculin Biotech, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Annamycin's superior efficacy in hard-to-treat AML and absence of cardiotoxicity offer meaningful clinical value, but capital scarcity and compressed timeline to data create a high-risk, high-reward binary outcome profile.

What is Moleculin Biotech, Inc.'s industry? Moleculin Biotech, Inc. (moleculin.com) operates in Oncology Drugs. AskCyborg classifies Moleculin Biotech, Inc. under Oncology Drugs in its company registry.

Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The company's lead program, Annamycin, is a next-generat...

4/ 10Mixed

Cyborg Score thesis

Annamycin's superior efficacy in hard-to-treat AML and absence of cardiotoxicity offer meaningful clinical value, but capital...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Moleculin Biotech, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Moleculin Biotech, Inc.

AskCyborg analysts argue the bull and bear cases for Moleculin Biotech, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Moleculin Biotech, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Moleculin Biotech, Inc. Overview

Pro stress-test →

Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. The company is advancing toward a pivotal inflection point with data readouts expected in the coming months.

Strategic Profile

Pro stress-test →

Moleculin is advancing its pivotal Phase 2/3 MIRACLE trial of Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia, with preliminary results from 62 evaluable subjects showing a composite complete remission rate of 37%. The MIRACLE trial is advancing toward planned 90-patient enrollment with unblinded efficacy readout expected in December 2026 to February 2027. The company maintains a lean operational footprint with limited cash runway, requiring rapid clinical validation for continued operations.

Competitive Landscape

Pro stress-test →

Moleculin competes in the oncology therapeutics space against larger, better-capitalized biotechs developing AML and solid tumor treatments. Direct competitors include clinical-stage and commercial-stage companies developing novel anthracyclines, STAT3 inhibitors, and immunotherapy combinations for hematologic and solid malignancies.

Industry Context

Moleculin Biotech, Inc. operates in Oncology Drugs.

Key facts

Founded: 2010 · Headquarters: Houston, Texas, US · Revenue: Estimated $0 (pre-revenue clinical-stage company) · Market cap: $11.1M (as of September 28, 2026)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Moleculin Biotech, Inc..

  • Moleculin's MIRACLE trial shows composite complete remission rates of 37% versus historical CR rates of 17-18% with cytarabine alone, suggesting a meaningful therapeutic advantage in relapsed/refractory AML treatment.
  • Preclinical data presented in 2026 show Annamycin produced significant tumor growth inhibition across multiple pancreatic ductal adenocarcinoma models with strong statistical significance, expanding potential market applications beyond AML.
+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Moleculin outlined accelerated business outlook with MIRACLE trial unblinding planned for Q1 2026 and global trial expansion across nine countries
  • May 2026Q1 2026 results showed MIRACLE enrollment surpassing first interim analysis threshold; company cash position of ~$10.3M with operations funded through Q3 2026
  • +2 moreTrack every material event for Moleculin Biotech, Inc. as it happens. Explore monitoring →
Get alerted when Moleculin Biotech, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ayala PharmaceuticalsClinical-stage biotech developing targeted oncology therapeutics for hematologic malignancies→Oncolytics BiotechClinical-stage biotech with pipeline for solid tumors and hematologic malignancies→Surface OncologyClinical-stage immuno-oncology biotech developing novel therapeutics for solid tumors and hematologic cancers→Umoja BiopharmaClinical-stage biotech developing cell therapy and small molecule therapeutics for hematologic malignancies→

Compare Moleculin Biotech, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Moleculin Biotech, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Moleculin Biotech, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Moleculin Biotech, Inc. and its top competitor on Cyborg Score”
“What did Moleculin Biotech, Inc. do this quarter?”
“Is Moleculin Biotech, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Moleculin Biotech, Inc. do?+
Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The company's lead program, Annamycin, is a next-generat...
What is Moleculin Biotech, Inc.'s Cyborg Score?+
Moleculin Biotech, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Moleculin Biotech, Inc.'s main competitors?+
Named competitors include Ayala Pharmaceuticals, Oncolytics Biotech, Surface Oncology, Umoja Biopharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Moleculin Biotech, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Moleculin Biotech, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Moleculin Biotech, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.